Compositions and methods of treating neuronal injury

Patent metadata

Field	Value
Publication number	US-2021069216-A1
Application number	US-202017015625-A
Country	US
Kind code	A1
Filing date	Sep 9, 2020
Priority date	Sep 9, 2019
Publication date	Mar 11, 2021
Grant date	—

Abstract

The present invention features methods and composition directed to treating neuronal injury, CNS lesion, and/or promoting axon regeneration using a phosphine sulfide-stabilized phosphine.

First claim

What is claimed is:

1 . A composition for treating a neuronal injury, the composition comprising a phosphine sulfide-stabilized phosphine and a pharmaceutically acceptable carrier excipient.

2 . The composition of claim 1 , wherein the phosphine sulfide-stabilized phosphine is PSP-1, PSP-2, phenPS, or naphPS.

3 . The composition of claim 1 , wherein the phosphine sulfide-stabilized phosphine is PSP-2.

4 . The composition of claim 1 , wherein the composition comprises an amount of a phosphine sulfide-stabilized phosphine sufficient to increase axon outgrowth subsequent to nerve injury relative to the amount of axon outgrowth detected in a corresponding control cell.

5 . A method for promoting axon regeneration, the method comprising contacting a neuron at a site of injury with a phosphine sulfide-stabilized phosphine.

6 . A method of treating a subject having a central nervous system lesion, the method comprising administering to the subject a phosphine sulfide-stabilized phosphine.

7 . The method of claim 6 , wherein the phosphine sulfide-stabilized phosphine is PSP-1, PSP-2, PhenPS, or naphPS.

8 . The method of claim 6 , wherein the phosphine sulfide-stabilized phosphine is PSP-2.

9 . The method of claim 6 , wherein the contacting or administering occurs prior to, during, or subsequent to the injury.

10 . The method of claim 9 , wherein the phosphine sulfide-stabilized phosphine is administered prior to a surgical procedure.

11 . The method of claim 9 , wherein the contacting or administering occurs within about 1, 6, 12, or 24 hours of the injury.

12 . The method of claim 9 , wherein the contacting or administering occurs within about 1-3 days of the injury.

13 . The method of claim 6 , wherein the administering is local or systemic.

14 . The method of claim 13 , wherein the administering is sustained for days, weeks, or months.

15 . The method of claim 6 , wherein the subject is a mammal.

16 . The method of claim 6 , wherein the subject is a human.

17 . The method of claim 6 , wherein the injury or CNS lesion results from an acute traumatic injury.

18 . The method of claim 19 , wherein the acute traumatic injury is selected from the group consisting of stroke, acute spinal cord injury, and traumatic brain injury.

19 . The method of claim 6 , wherein the lesioned CNS neuron is in the optic nerve.

20 . The method of claim 6 , wherein administration is ocular.

21 . The method of claim 6 , wherein the lesioned CNS neuron is in the spinal cord of a patient, and the inhibitor is intrathecally administered to the patient.

22 . The method of claim 6 , wherein the lesioned CNS neuron is a sensory neuron.

Assignees

• Childrens Medical Center
• Georgia Tech Res Inst

Inventors

• Sergeeva Elena G
• Rosenberg Paul A
• Benowitz Larry I
• Fahrni Christoph J
• Morgan Thomas

Classifications

• A61K9/0048

  Eye, e.g. artificial tears · CPC title

• A61K31/66 Primary

  Phosphorus compounds · CPC title

• A61P25/00 Primary

  Drugs for disorders of the nervous system · CPC title

• A61K9/0085

  Brain, e.g. brain implants; Spinal cord · CPC title